Microbiology, resistance patterns, and risk factors of mortality in ventilator-associated bacterial pneumonia in a Northern Thai tertiary-care university based general surgical intensive care unit

Kaweesak Chittawatanarat
Wuttipong Jaipakdee
Narain Chotirosniramit
Kantone Chandacham
Tidarat Jirapongcharoenlap

Division of Surgical Critical Care and Trauma, Department of Surgery, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

Background: Ventilator-associated pneumonia (VAP) occurrence, causative pathogens, and resistance patterns in surgical intensive care units (SICU) are different between Western and developing Asian countries. In Thailand, resistant organisms have progressively increased in the last decade. However, the evidence describing causes of VAP and its outcomes, especially secondary to resistant pathogens, in Asian developing countries’ SICUs is very limited. Therefore, the objective of this study was to describe the incidence, pathogen characteristics, and risk factors that impact mortality and patient survival following VAP in a tertiary Northern Thai SICU.

Methods: Between 2008 and 2012, VAP occurred in a total of 150 patients in Chiang Mai University’s general SICUs (6.3 ± 2.8 cases per 1,000 mechanical ventilator days). The following clinical data were collected from 46 patients who died and 104 patients who survived: microbiologic results, susceptible patterns, and survival status at hospital discharge. Antimicrobial susceptibility patterns were classified as susceptible, multidrug resistant (MDR), extensively drug resistant (XDR), and pan-drug resistant (PDR). The hazard ratio (HR) was calculated for risk factor analysis.

Results: Regarding the microbiology, gram negative organisms were the major pathogens (n=142, 94.7%). The first three most common organisms were Acinetobacter baumannii (38.7% of all organisms, mortality 41.4%), Klebsiella pneumoniae (17.3%, mortality 30.8%), and Pseudomonas aeruginosa (16.7%, mortality 16%) respectively. The most common gram positive organism was Staphylococcus aureus (4.0%, mortality 50%). The median day of VAP occurrence were significantly different between the three groups (P<0.01): susceptible (day 4), MDR (day 5), and XDR (day 6.5). Only half of all VAP cases were caused by susceptible organisms. Antibiotic resistance was demonstrated by 49.3% of the gram negative organisms and 62.5% of the gram positive organisms.

Extensive drug resistance was evident only in Acinetobacter baumannii (30.6%) and Pseudomonas aeruginosa (1.3%). No pan-drug resistance was found during surveillance. The significant HR risk factors were age (P=0.03), resistant organisms (P=0.04), XDR (P=0.02), and acute physiology and chronic health evaluation II score (<0.01). Acinetobacter baumannii (P=0.06) and intubation due to severe sepsis (P=0.08) demonstrated a trend toward a significant increase in the HR. On the other hand, there were significantly decreased HRs in trauma patients (P=0.01). Initial administration of appropriate antibiotic therapy had a tendency toward a significant decrease in the HR (P=0.08).

Conclusion: Gram negative organisms were the primary cause of bacterial VAP in Chiang Mai University’s general SICU. Resistant strains were present in half of all VAP cases and were associated with the day of VAP onset. Regarding risk factors, age, acute physiology, chronic health evaluation II score, resistant organisms (especially XDR), and being a non-trauma patient increased the risk of mortality.

Keywords: surgical intensive care unit, ventilator-associated pneumonia, device-related incidence rate, drug resistant organism, Acinetobacter baumannii

This article was published in the following Dove Press journal:
Infection and Drug Resistance
16 August 2014
Number of times this article has been viewed
Introduction
The mechanical ventilator (MV) provides the most common organ support in an intensive care unit (ICU). The prevalence of patients requiring a MV in a Thai surgical ICU (SICU) survey was found to be 56.0%.¹ One of the most common complications whilst on a MV was ventilator-associated pneumonia (VAP), creating a burden in overall health care costs.² The incidence and mortality rates of VAP vary due to several factors such as the study population, time of onset, causative organisms, and appropriate antibiotic therapy.³ There were differences in the incidence of causative VAP organisms between Western and Asian developing countries.⁴⁻⁵ In most Western hospital SICUs, gram positive organisms, especially methicillin-resistant Staphylococcus aureus (MRSA), are the prominent pathogens.⁶⁻⁸ This is in contrast to most of Asian developing countries where the most common pathogens were gram negative organisms and evidence also showed an increase in drug resistant strains.⁹⁻¹⁰ However, there are few existing reports on these pathogens’ characteristics in the context of SICUs in Asian developing countries. Therefore, the objective of this study was to describe the incidence, pathogen characteristics, and risk factors which impact mortality and survival in patients who developed VAP in our SICU.

Material and methods
The authors collected 5 years of prospective surveillance data from the SICU and sub-SICU in a 1,400 bed university-based hospital in the Northern region of Thailand. There were 21 adult SICU beds and sub-SICU beds in the division of surgical critical care and trauma. These ICUs accommodate vascular, trauma, thoracic, and abdominal surgical patients. Surveillance data were retrieved from the hospital infectious control (IC) data registry. IC working groups were comprised of multi-departmental coordinator physicians, IC nurses (ICN), and IC ward coordinator nurses (ICWs). In SICU, seven ICWs followed and inspected all nosocomial infection (NI) occurrences based on standard international criteria. The IC coordinator of critical care surgeons confirmed all new NI cases. The hospital IC regularly collected all cases of NI and reported them monthly to an IC committee.

Diagnosis of VAP
VAP diagnosis was defined as pneumonia occurring more than 48 hours after patients had been intubated and received mechanical ventilation, as well as using American Thoracic Society criteria which is comprised of three groups of criteria as clinical, radiographic, and microbiological criteria.¹¹⁻¹⁰ The criteria included a new and persistent infiltration present for more than 48 hours on a chest radiograph, plus two or more of the following: 1) fever of more than 38°C or less than 36°C; 2) leukocytosis of more than 10,000 or leucopenia of less than 5,000 cells/mL; 3) purulent tracheobronchial secretion; and 4) gas exchange degradation. Positive microbiological culture confirmation was also required. All of our culture specimens were collected by endotracheal aspiration. All sputum cultures of the specimens were interpreted by the surgical critical care attending physician based on definition criteria.¹¹ Patients with only initial clinical suspicion and negative culture result were excluded from surveillance. Late onset of VAP was defined as VAP occurring more than 4 days (>96 hours) after intubation.¹²

Definition of resistance and appropriate antibiotic therapy
Definition of resistance in this study was based on the criteria specified by European Center for Disease Prevention and Control and the Center for Disease Control and Prevention (CDC).¹³ Multidrug resistant (MDR) was defined as resistance to at least one agent in three or more antimicrobial categories. Extensively drug resistant (XDR) was defined as resistance to at least one agent in all but two or fewer antimicrobial categories. Pan-drug resistant (PDR) was defined as resistance to all agents in all antimicrobial categories.¹⁴ In addition, extended spectrum beta lactamasmes (ESBLs) were gram negative bacteria which were non-susceptible to first-, second-, and third-generation cephalosporins and monobactams but are not affected by cephemycins or carbapenem antimicrobial agents.¹⁴ MRSA is the strain of Staphylococcus aureus resistant to methicillin and other more common antibiotics such as oxacillin, penicillin, and amoxicillin.¹⁵ ESBLs and MRSA were classified as MDR in this study. The in vitro antibiotic susceptibility was determined by the antibiotic disc diffusion test. Dilution test using Minimal Inhibitory Concentration (MIC) was not performed in this study. Patients receiving appropriate antibiotic therapy were defined as receiving empirical antimicrobial agent(s) which the organism was sensitive to, within 24 hours of the time of VAP diagnosis, before reporting of the culture result.

Study design and statistical analysis
This study was a retrospective analysis of all patients who developed VAP, reported to the IC surveillance system, between 1 January 2008 and 31 December 2012. The Faculty of Medicine, Chiang Mai University Ethics Committee approved this study. The authors collected sex,
Results

During a 5 year period, a total of 23,546 mechanical ventilator days (MVD) (4,709±266.4 MVD/year) were observed in the general SICU and sub-SICU. The surveillance center collected a total of 150 VAP patients during this period. The average VAP incidence density rate during this period was 6.3±2.8 cases per 1,000 MVD. The median of VAP onset occurred on day 5 after intubation (IQR day 3–8). Forty-six patients (30.7%) died in hospital after VAP diagnosis (Table 1). The patients who did not survive were significantly older than the patients who survived (mean±SD: 59.5±19.0 years and 49.4±20.7 years; P<0.01). The overall median ICU and hospital length of stay in days (IQR) was 19.0 (13–34) and 26.0 (16–43) respectively. However, there were no differences between the length of stay between the mortality group and the survival group. The top three comorbidities of VAP patients were cardiovascular disease, diabetes, and hypertension respectively. Nearly two thirds (62.7%) of VAP occurred in trauma patients. Trauma patients had a significantly lower mortality rate than non-trauma patients (trauma versus non-trauma 20.2% versus 48.2%; P<0.001). The top four major reasons for intubation were as follows: an alteration of consciousness (60.58%), postoperatively (22.0%), severe sepsis (8.7%), and hypovolemic shock (8.7%). The major locations of the first intubation occurred in the referring hospital (44.67%), operating room (24.0%), and ICU (15.33%). Regarding the onset of VAP, onset after intubation, and susceptibility patterns, the median of the onset day (IQR) was significantly different among the VAP organisms (susceptible versus MDR versus XDR: 4 days (3–6) versus 5 days (3–8) versus 6.5 days (4–12); P<0.01).

Regarding the microbiology, gram negative bacteria were the major pathogens (94.7%) and gram positive organisms were only 5.3%. There were no fungal infections reported during this study. Of these gram negative bacteria, the first three most common organisms were Acinetobacter baumannii (38.7% of all VAP/mortality 41.4%), Klebsiella pneumoniae (17.3%/mortality 30.8%) and Pseudomonas aeruginosa (16.7%/mortality 16%). The most common gram positive organism was Staphylococcus aureus (4.0%/mortality 50%).

Regarding the drug sensitivity pattern, the numbers in the susceptible versus MDR versus XDR: 4 days (3–6) versus 5 days (3–8) versus 6.5 days (4–12); P<0.01).

### Table 1 Characteristics of patients with VAP in an SICU

| Characteristic | All (n=150) | Death (n=46) | Survived (n=104) | P-value |
|---------------|------------|-------------|-----------------|---------|
| Male (%)      | 106 (70.7) | 31 (67.4)   | 75 (72.1)       | 0.56    |
| Age in years  | 59.6 (19.0)| 49.5 (20.8) | 59.6 (19.0)     | <0.01   |
| APACHE II score (SD) | 19.7 (4.0) | 21.6 (4.0)  | 18.7 (3.8)      | <0.01   |
| ICU LOS in days, median (IQR) | 19.0 (13–34) | 24.5 (11–39) | 17.0 (13–28.5) | 0.21    |
| Hospital LOS in days, median (IQR) | 26.0 (16–43) | 26.0 (16–43) | 26.0 (16–43) | 0.44    |
| Type of patients, n (%) | | | |
| Non-trauma | 56 (37.3) | 27 (58.7) | 29 (27.9) | <0.01 |
| General | 31 (20.7) | 18 (39.1) | 13 (26.5) | 12 (11.5) |
| Vascular | 18 (12.0) | 6 (13.0) | 12 (11.5) | |
| Thoracic (non-cardiac) | 7 (4.7) | 3 (6.5) | 4 (3.9) | |
| Trauma | 94 (62.7) | 19 (41.3) | 75 (72.1) | |
| Neurosurgical | 73 (48.7) | 11 (23.9) | 62 (59.6) | |
| Non-neurosurgical | 21 (14.0) | 8 (17.4) | 13 (12.5) | |
| Comorbidities, n (%) | | | |
| Diabetes | 13 (8.7) | 6 (13.0) | 7 (6.7) | 0.22 |
| Hypertension | 9 (6.0) | 4 (8.7) | 5 (4.8) | |
| Cardiovascular | 16 (10.7) | 4 (8.7) | 12 (11.5) | |
| Chronic lung disease | 8 (5.3) | 5 (10.9) | 3 (2.9) | |
| Cirrhosis | 4 (2.7) | 3 (6.5) | 1 (1.0) | |
| Others | 6 (4.0) | 2 (4.3) | 4 (3.8) | |
| Cause of intubation, n (%) | | | |
| Postoperative | 33 (22.0) | 11 (23.9) | 22 (21.2) | <0.01 |
| Alteration of consciousness | 73 (48.7) | 10 (21.7) | 63 (60.6) | |
| Severe sepsis | 13 (8.7) | 8 (17.4) | 5 (4.8) | |
| Hypovolemic shock | 13 (8.7) | 6 (13.1) | 7 (6.7) | |
| Pulmonary edema | 5 (3.3) | 3 (6.5) | 2 (1.9) | |
| Others | 13 (8.7) | 8 (17.4) | 5 (4.8) | |

Abbreviations: APACHE, Acute Physiology of Chronic and Health Evaluation; ICU, intensive care unit; LOS, length of stay; SD, standard deviation; IQR, interquartile range; VAP, ventilator-associated pneumonia; SICU, surgical intensive care unit.
proportion of drug susceptibility of each organism. *Proteus mirabilis, Stenotrophomonas spp. Streptococcus pneumoniae, Citrobacter koseri* and, *Pasteurella spp.* were non-MDR organisms. The remaining pathogens had varying levels of drug resistance for each pathogen (*Acinetobacter baumannii* [82.8%], *Enterobacter* spp. [42.9%], *Escherichia coli* [33.3%], *Klebsiella pneumonia* [30.8%], *Pseudomonas aeruginosa* [28%], *Haemophilus influenzae* [13.3%], *Staphylococcus aureus* [66.7%], and *Enterococcus faecium* [100%]; Figure 1).

Only one VAP patient was infected by a drug resistant strain of *Enterococcus faecium*. Overall the mortality of the DR group was significantly higher than the sensitivity group (41.3% resistant group versus 20.0% susceptible group; *P*, 0.01). XDR gram negative bacteria occurred in one third of the total VAP patients and also showed a significantly higher rate of mortality than the sensitivity group (*P*, 0.01). *Acinetobacter baumannii* (46/50 [92%]) and *Pseudomonas aeruginosa* (4/50 [8%]) were the only two gram negative XDR organisms. There were no XDR gram positive bacteria (**Table 2**). No mortality was reported in patients who were infected with *Haemophilus influenzae* and *Pasteurella* spp. There was no resistance in our specimens in the following cases: bacteriogram, colistin for gram negative bacteria, and vancomycin for gram positive bacteria. Bacteriogram sensitivity between 50%–60% were carbapenem (imipenem-cilastatin acid [60.8%], meropenem [60.9%]), cefoperazone-sulbactam (60.5%), piperacillin-tazobactam (58.1%), and levofloxacin (52.6%) and less than 50% were cefotaxime (41.6%), ciprofloxacin (49.6%), and amoxicillin-clavulanic acid (28.1%). Both clindamycin and oxacillin had bacteriogram activity in only one third of the gram positive bacteria cases.

For the risk factor analysis in **Table 3**, the significantly increased HR parameters were age (HR 1.02; *P*, 0.03), resistant organisms (HR 1.93; *P*, 0.04), XDR (HR 2.22; *P*, 0.02), and APACHE II score (HR 113; *P*, 0.01). *Acinetobacter baumannii* (HR 1.76; *P*, 0.06) and intubation due to severe sepsis (HR 2.00; *P*, 0.08) trended toward a significant increase of HR. In contrast, trauma patients (HR 0.47; *P*, 0.01) and the initial administration of appropriate antibiotic therapy (HR 0.59; *P*, 0.08) had a significantly and trend decreased HR respectively. **Figure 2** demonstrates the survival time of patients with some risk factors including drug susceptibility pattern (sensitive versus MDR versus XDR), type of surgical patients (trauma versus non-trauma), administration of appropriate antibiotic (appropriate versus inappropriate), and organism type (*Acinetobacter baumannii* versus others).

**Discussion**

Different studies reported varied VAP incidence rates ranging from 5% to 67%, which may be confounded by the
Infection and Drug Resistance 2014:7

Table 2 Organism involved in VAP in an SICU

| Organism types, n (%) | All (n=150) | Death (n=46) | Survived (n=104) | P-value |
|-----------------------|-------------|--------------|------------------|---------|
| Gram negative         | 142 (94.7)  | 43 (93.48)   | 99 (95.2)        | 0.67    |
| Gram positive         | 8 (5.3)     | 3 (6.5)      | 5 (4.8)          |         |
| Gram negative organisms |            |              |                  |         |
| Acinetobacter baumannii | 58 (38.7)  | 24 (52.2)    | 34 (32.7)        | <0.01   |
| Klebsiella pneumoniae  | 26 (17.3)   | 8 (17.4)     | 18 (17.3)        |         |
| Pseudomonas aeruginosa | 25 (16.7)   | 4 (8.7)      | 21 (20.2)        |         |
| Haemophilus influenzae | 15 (10.0)   | 0 (0)        | 15 (14.4)        |         |
| Enterobacter spp.      | 7 (4.7)     | 2 (4.3)      | 5 (4.8)          |         |
| Escherichia coli       | 6 (4.0)     | 1 (2.1)      | 5 (4.8)          |         |
| Stenotrophomonas spp.  | 2 (1.3)     | 2 (4.3)      | 0 (0)            |         |
| Citrobacter koseri     | 1 (0.7)     | 1 (2.2)      | 0 (0)            |         |
| Pasteurella spp.       | 1 (0.7)     | 0 (0)        | 1 (1.0)          |         |
| Proteus mirabilis      | 1 (0.7)     | 1 (2.2)      | 0 (0)            |         |
| Gram positive organisms |            |              |                  |         |
| Staphylococcus aureus  | 6 (4.0)     | 3 (6.5)      | 3 (2.9)          | 0.45    |
| Enterococcus faecium   | 1 (0.7)     | 0 (0)        | 1 (1.0)          |         |
| Streptococcus          | 1 (0.7)     | 0 (0)        | 1 (1.0)          |         |
| Pneumoniae             | 1 (0.7)     | 1 (2.2)      | 0 (0)            |         |
| Antibiotic susceptibility, n (%) |         |              |                  |         |
| Susceptible pattern    |             |              |                  | <0.01   |
| Susceptible organisms  | 75 (50.0)   | 15 (32.6)    | 60 (57.7)        |         |
| Resistant organisms    | 75 (50.0)   | 31 (67.4)    | 44 (42.3)        |         |
| Appropriate antibiotics |            |              |                  |         |
| Inappropriate           | 61 (40.7)   | 26 (56.5)    | 35 (33.6)        | <0.01   |
| Appropriate            | 89 (59.3)   | 20 (43.5)    | 69 (66.4)        |         |
| Gram negative          | 142 (94.7)  | 43 (93.5)    | 99 (95.2)        | 0.02    |
| Susceptible organisms  | 72 (48.0)   | 14 (30.4)    | 58 (55.8)        |         |
| MDR organisms          | 20 (13.3)   | 6 (13.0)     | 14 (13.5)        |         |
| XDR organisms          | 50 (33.3)   | 23 (50.0)    | 27 (26.0)        |         |
| Gram positive          | 8 (5.3)     | 3 (6.5)      | 5 (4.8)          | 0.64    |
| Susceptible organisms  | 3 (2.0)     | 1 (2.2)      | 2 (1.9)          |         |
| MDR organisms          | 5 (2.7)     | 2 (4.3)      | 3 (2.8)          |         |
| Implementation of VAP prevention, n (%) |   |             |                  |         |
| Before (2008–2010)     | 103 (68.7)  | 28 (60.9)    | 75 (72.1)        | 0.17    |
| After (2011–2012)      | 47 (31.3)   | 18 (39.1)    | 29 (27.9)        |         |

Abbreviations: MDR, multidrug resistant; XDR, extensively drug resistant; VAP, ventilator-associated pneumonia; SICU, surgical intensive care unit.

Table 3 Hazard ratio of mortality following VAP

| Hazard ratio (95% confidence interval) | P-value |
|---------------------------------------|---------|
| Male                                  | 0.93 (0.50–1.72) | 0.81    |
| Age                                   | 1.02 (1.00–1.03) | 0.03    |
| Initial APACHE II score               | 1.13 (1.05–1.23) | <0.01   |
| Late onset                            | 1.43 (0.79–2.60) | 0.24    |
| Resistant organisms                   | 1.93 (1.04–3.59) | 0.04    |
| MDR                                   | 1.39 (0.59–3.31) | 0.45    |
| XDR                                   | 2.22 (1.16–4.27) | 0.02    |
| Appropriate antibiotic                | 0.59 (0.33–1.06) | 0.08    |
| Gram negative                         | 0.88 (0.27–2.85) | 0.83    |
| Acinetobacter baumannii               | 1.76 (0.98–3.13) | 0.06    |
| Klebsiella pneumoniae                 | 1.09 (0.51–2.35) | 0.82    |
| Pseudomonas aeruginosa                | 0.42 (0.15–1.18) | 0.10    |
| Escherichia coli                      | 0.58 (0.08–4.22) | 0.59    |
| Enterobacter spp.                     | 0.86 (0.21–3.58) | 0.84    |
| Staphylococcus aureus                 | 1.63 (0.50–5.29) | 0.41    |
| Trauma                                | 0.47 (0.26–0.85) | 0.01    |
| Diabetic                              | 1.43 (0.60–3.37) | 0.42    |
| Cardiovascular                        | 0.91 (0.42–1.95) | 0.80    |
| Intubation due to severe sepsis       | 2.00 (0.93–4.33) | 0.08    |
| Intubation due to hypovolemic shock   | 1.68 (0.71–3.96) | 0.24    |
| Postoperative intubation              | 0.81 (0.41–1.60) | 0.54    |
| Implementation of VAP prevention     |         |         |
| Susceptible organisms                 | 1.21 (0.38–3.84) | 0.74    |
| MDR                                   | 1.51 (0.28–8.25) | 0.64    |
| XDR                                   | 1.83 (0.80–4.18) | 0.15    |

Abbreviations: APACHE, Acute Physiology of Chronic and Health Evaluation; MDR, multidrug resistant; XDR, extensively drug resistant; VAP, ventilator-associated pneumonia.

The presence of mixed populations with variable age groups, underlying conditions, other associated risk factors, and using different gold standards for diagnosis.16 The National Nosocomial Infections Surveillance System of the CDC reported the median rate of VAP cases per 1,000 MVD in the US was higher in SICUs (range 6.2–11.4) than in medical ICUs (3.7).17 In Asian countries, the incidence density of VAP varied between 3.5–9.0 cases per 1,000 MVD.5 The incidence of VAP over a 5 year period of surveillance in our SICU was comparable with rates reported by the CDC and the Asian reports (6.3±2.8 cases per 1,000 MVD). Trauma patients had a higher occurrence of VAP than non-trauma patients (trauma versus non-trauma: 62.7% versus 38.3%). This finding was in keeping with the higher incidence rate in trauma patients reported by the CDC.17

The most common bacterial pathogen causing ventilator-associated bacterial pneumonia in a Western surveillance program was Staphylococcus aureus with an incidence varying from 30%–45%, of which MRSA accounts for 20%–40%.5 In most Asian countries, MRSA infection was less than 20%.5 However, in Thailand, our results found MRSA incidence was less than 10%.5,18 A recent study showed that in the VAP incidence of mixed medical-SICUs in Thailand, gram negative bacteria were the most common organisms particularly Acinetobacter baumannii (25%–50%), Pseudomonas aeruginosa (18%–35%), and Klebsiella pneumoniae (7%–25%), which were comparable with our results in SICU.5,18,19 In the authors’ opinion, these phenomena might be explained by environmental climate, eg, gram negative organisms, especially Acinetobacter baumannii, could more rapidly colonize in a warm and humid environment found in tropical regions. In addition, transient bacteremia from skin flora, induced by invasive monitoring, might be an
explanatory factor. Although there were no data on the number and duration of arterial or central venous line insertions in this study, the possible higher number of these line insertions for any purposes of invasive monitoring in Western countries might be a mediating factor for higher incidence of gram positive infection of VAP in developed countries. Interestingly, the drug resistant gram negative *Pseudomonas aeruginosa* was also commonly cited in Western reports. However, the frequency of the occurrence of this organism was less than *Acinetobacter baumannii* in Asian countries including Thailand. XDR strains or Carbapenem resistant *Acinetobacter baumannii* have progressively increased in the last decade. This tendency corresponded to our results that more than 80% of these organisms were resistant to the usual gram negative antimicrobial agents and more than 90% of these were XDR. A stratification scoring system for guiding antibiotic therapy might increase appropriate empirical therapy. However, the antimicrobial drug of choice might be different based on local epidemiological data. In addition, although the burden of *Staphylococcus aureus* VAP in this study was small, the mortality rate was also high in this study. The early detection and appropriate antimicrobial therapy should be initiated and managed as soon as possible.

The mortality rate in our SICU was 30.6% and significantly lower in trauma patients (trauma versus non-trauma: 20.2% versus 48.2%). Recent meta-analysis reported the same finding but showed a lower mortality rate than our data (trauma versus non-trauma: 13.3% versus 33.2%). APACHE II scores and patient age were the important independent risk factors for VAP mortality in previous reports. However, the significant effect of *Acinetobacter baumannii* was small and demonstrated a tendency of increasing risk; the obvious results require a larger sample size of infected patients. On the other hand, resistant bacteria significantly increased mortality in a previous report. In addition, appropriate antibiotic therapy could significantly decrease mortality in both first and recurrent episodes. Most cases of inappropriate antibiotic therapy occurred in XDR patients. Therefore, suspected XDR infection should be treated with empiric broad spectrum antibiotics based on local guidance. The VAP onset was one of the independent factors of XDR and this might be a concerning factor for selection and initiating broad spectrum antimicrobial agents. The authors suggest that mortality may be decreased by choosing appropriate antibiotic therapy for drug resistant bacteria based on the time of VAP onset and gram strain identification. The occurrence of gram positive VAP organisms was low. The effect on mortality was high but it was not statistically significant. The reason behind this was a small sample size, which resulted in less valid results.

The strength of this study was the 5 year surveillance data which sub-classified the drug resistance and demonstrated the effects on mortality in SICU. This report

---

**Figure 2** Kaplan–Meier survival estimation of mortality in VAP patients.

**Notes:** (A) Trauma patients, (B) appropriate antibiotics, (C) *Acinetobacter baumannii*, and (D) susceptible patterns of organisms.

**Abbreviations:** VAP, ventilator-associated pneumonia; MDR, multidrug resistant; XDR, extensively drug resistant.
was the first analysis of the impact of VAP in a Thai SICU. However, there were some inevitable limitations. Firstly, the incidence of VAP varied because preventive VAP bundle strategies (bed elevation of more than 30 degrees, using weaning of MV protocol, ensuring appropriate cuff pressure measurement, chlorhexidine oral rinse, sedation holiday, and early ambulation) were implemented during the last 2 years of surveillance. Although VAP occurrence decreased from 34.3 to 23.5 cases per year (Table 2), there was no significant difference on HR of mortality between before and after preventive VAP bundle strategies implementation (Table 3). Secondly, the surveillance data reported only the major pathogen on the culture report according to the attending physician’s opinion. Therefore, we did not report poly-microbial VAP incidence. However, the epidemiology and outcomes of patients did not differ regarding mono- or poly-microbial VAP. Finally, because of limited resources, all of the microscopic culture specimens were collected from endotracheal sputum aspiration. These might be discordant if compared to using more accurate bronchoscopic alveolar lavage. However, the accordance results between endotracheal sputum aspiration and bronchoscopic alveolar lavage results of previous reports in trauma patients between these two methods were 83% for gram strain and 73% for culture reports.

Conclusion
Gram negative organisms were the major cause of bacterial VAP in Chiang Mai University’s general SICUs. Resistant strains are present in half of all VAP cases and were associated with its onset. Regarding risk factors, age, APACHE II score, resistant organisms (especially XDR) and being a non-trauma patient increased the risk of mortality.

Author contributions
K Chittawatanarat and W Jaipakdee drafted the manuscript, participated in the study design, and performed the statistical analysis. N Chotirosniramit, K Chandacham, and T Jirapongcharoenlap participated in co-ordination and prospective data collection. All authors contributed toward data analysis, drafting, and revising the manuscript.

Acknowledgments
The authors would like to thank the Infection Control Unit of the Faculty of Medicine, Chiang Mai University Hospital. We give our grateful thanks to all of the infection control nurses in the SICU for their assistance in providing the surveillance data.

Disclosure
The authors have no conflicts of interest to declare.

References
1. Chittawatanarat K, Jaikriengkrai K, Permpikul C, Thai Society of Critical Care Study group. Survey of respiratory support for intensive care patients in 10 Tertiary hospital of Thailand. J Med Assoc Thai. 2014;97(Suppl 1):S8–S14.
2. Wilke M, Grube R. Update on management options in the treatment of nosocomial and ventilator assisted pneumonia: review of actual guidelines and economic aspects of therapy. Infect Drug Resist. 2013;7:1–7.
3. American Thoracic Society. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2005;171(4):388–416.
4. Jones RN. Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis. 2010;51(Suppl 1):S81–S87.
5. Chawla R. Epidemiology, etiology, and diagnosis of hospital-acquired pneumonia and ventilator-associated pneumonia in Asian countries. Am J Infect Control. 2008;36(Suppl 4):S93–S100.
6. Minei JP, Nathens AB, West M, et al. Inflammation and the Host Response to Injury, a Large-Scale Collaborative Project: patient-oriented research core – standard operating procedures for clinical care. II. Guidelines for prevention, diagnosis and treatment of ventilator-associated pneumonia (VAP) in the trauma patient. J Trauma. 2006;60(5):1106–1113.
7. Zygun DA, Zuege DJ, Boiteau PJ, et al. Ventilator-associated pneumonia in severe traumatic brain injury. Neurocrit Care. 2006;5(2):108–114.
8. Hamilton LA, Christopher Wood G, Magnotti LJ, et al. Treatment of methicillin-resistant Staphylococcus aureus ventilator-associated pneumonia with high-dose vancomycin or linezolid. J Trauma Acute Care Surg. 2012;72(6):1478–1483.
9. Apisarnthanarak A, Buppunharun W, Tiengrim S, Sawanpanyalert P, Aswapokee N. An overview of antimicrobial susceptibility patterns for gram-negative bacteria from the National Antimicrobial Resistance Surveillance Thailand (NARST) program from 2000 to 2005. J Med Assoc Thai. 2009;92(Suppl 4):S91–S94.
10. Koenig SM, Truwit JD. Ventilator-associated pneumonia: diagnosis, treatment, and prevention. Clin Microbiol Rev. 2006;19(4):637–657.
11. Morris AJ, Tanner DC, Keller LB. Rejection criteria for endotracheal aspirates from adults. J Clin Microbiol. 1993;31(5):1027–1029.
12. Kollef MH, Silver P, Murphy DM, Trevillion E. The effect of late-onset ventilator-associated pneumonia in determining patient mortality. Chest. 1995;108(5):1655–1662.
13. Magiorakos AP, Srinivasan A, Carey RB, et al. Multidrug-resistant, extensively drug-resistant, pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect. 2012;18(3):268–281.
14. Paterson DL, Bonoño RA. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev. 2005;18(4):657–686.
15. Gorwitz RJ, Krouzon-Moran D, McAllister SK, et al. Changes in the prevalence of nasal colonization with Staphylococcus aureus in the United States, 2001–2004. J Infect Dis. 2008;197(9):1226–1214.
16. McCrory R, Jones DS, Adair CG, Gorman SP. Pharmaceutical strategies to prevent ventilator-associated pneumonia. J Pharm Pharmacol. 2003;55(4):411–428.
17. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from Jan 1992 through Jun 2004, issued Oct 2004. Am J Infect Control. 2004;32(8):470–485.
18. Reecheapichitkul W, Phondongnok S, Bourpoern J, Chaimanee P. Causative agents and resistance among hospital-acquired and ventilator-associated pneumonia patients at Siriraj Hospital, northeastern Thailand. Southeast Asian J Trop Med Public Health. 2013;44(3):490–502.
19. Werarak P, Kiratisin P, Thamlikitkul V. Hospital-acquired pneumonia and ventilator-associated pneumonia in adults at Siriraj Hospital: etiology, clinical outcomes, and impact of antimicrobial resistance. *J Med Assoc Thai*. 2010;93(Suppl 1):S126–S138.

20. Parker CM, Kutsogiannis J, Muscedere J, et al. Ventilator-associated pneumonia caused by multidrug-resistant organisms or Pseudomonas aeruginosa: prevalence, incidence, risk factors, and outcomes. *J Crit Care*. 2008;23(1):18–26.

21. Garnacho-Montero J, Amaya-Villar R. Multiresistant Acinetobacter baumanii infections: epidemiology and management. *Curr Opin Infect Dis*. 2010;23(4):332–339.

22. Melsen WG, Rovers MM, Groenwold RH, et al. Attributable mortality of ventilator-associated pneumonia: a meta-analysis of individual patient data from randomised prevention studies. *Lancet Infect Dis*. 2013;13(8):665–671.

23. Celis R, Torres A, Gatell JM, Almela M, Rodríguez-Roisin R, Agustí-Vidal A. Nosocomial pneumonia. A multivariate analysis of risk and prognosis. *Chest*. 1988;93(2):318–324.

24. Dupont H, Mentec H, Sollet JP, Bleichner G. Impact of appropriateness of initial antibiotic therapy on the outcome of ventilator-associated pneumonia. *Intensive Care Med*. 2001;27(2):355–362.

25. Mueller EW, Hanes SD, Croce MA, Wood GC, Boucher BA, Fabian TC. Effect from multiple episodes of inadequate empiric antibiotic therapy for ventilator-associated pneumonia on morbidity and mortality among critically ill trauma patients. *J Trauma*. 2005;58(1):94–101.

26. Caricato A, Montini L, Bello G, et al. Risk factors and outcome of Acinetobacter baumanii infection in severe trauma patients. *Intensive Care Med*. 2009;35(11):1964–1969.

27. Combes A, Figliolini C, Trouillet JL, et al. Incidence and outcome of polymicrobial ventilator-associated pneumonia. *Chest*. 2002;121(5):1618–1623.

28. Michetti CP, Aldaghlas T. Differences in management and mortality with a bronchoalveolar lavage-based diagnostic protocol for ventilator-associated pneumonia. *J Trauma Acute Care Surg*. 2012;72(1):242–246.